Background With several million microbes per square centimetre of skin, the task of mapping the physiological cutaneous microbiome is enormous. Indeed, the reliance on bacterial culture to identify cutaneous bacterial communities has led to a systematic underappreciation of cutaneous microbial diversity, potentially limiting our understanding of common inflammatory skin diseases, including psoriasis. However, based heavily on developments in molecular biology and bioinformatics, including next-generation sequencing, the last decade has witnessed a marked increase in our understanding of the extent and composition of the cutaneous microbiome. It is already clear that skin-specific (skin site and skin microenvironment), individual-specific (hygiene, sex, age and hormonal status), disease-specific (atopic eczema, acne) and genetic factors can all influence the cutaneous microbiome, albeit to varying and, as yet, ill-defined extents. Objectives To investigate the role of the microbiome in psoriasis and to outline how microbiome studies can be harnessed to provide new insights into disease pathogenesis and treatment selection. Methods This review briefly describes the process of 16S ribosomal RNA sequencing and then charts our current understanding of the cutaneous microbiome in health and the alterations (dysbiosis) associated with chronic inflammatory diseases, with particular reference to psoriasis. Results The possibility and clinical relevance of intraindividual cross-talk between the various microbiomes is discussed and potential mechanisms underpinning the interactions between resident skin flora and the immune system are highlighted. Conclusions Ultimately, in the age of personalized medicine, the integration of cutaneous microbiome signatures and comprehensive disease and drug response endotypes will herald a novel approach in the clinical management of chronic multisystem inflammatory diseases.
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What's already known about this topic?
• The human integument hosts an extensive microbial ecosystem, which has been underestimated owing to the reliance on bacterial culture for its identification.
• 16S ribosomal RNA sequencing has shed new light on the extent and diversity (interindividual and intraindividual) of the cutaneous microbiome and its potential role in health and chronic inflammatory diseases, including psoriasis.
• The mechanisms underpinning interactions between resident skin flora and the immune system are not completely understood.
What does this study add?
• This review outlines the evidence for, and clinical relevance of, differences in the composition of cutaneous microbiota in terms of inflammatory skin disease.
• In the age of personalized medicine, the integration of cutaneous microbiome signatures, combined with comprehensive genotyping and phenotyping of patients and their diseases, may facilitate treatment selection and consequently optimize treatment efficacy.
With a surface area of approximately 2 m 2 and containing an estimated 5 million hair follicles, 1 human skin plays host to a bewildering microbial ecosystem. It has been claimed that each square centimetre of skin may contain up to 2 million bacteria. 2 However, the extent and diversity of the cutaneous microbiome has been profoundly underestimated because of a reliance on bacterial culture to demonstrate its existence, reportedly identifying only 10% of the bacteria present on skin. 3 Advances in molecular biology, coupled with the development of complex bioinformatics tools, have revolutionized our understanding of the extent and composition of the cutaneous microbiome. 4, 5 Specifically, the use of high-throughput sequencing, exploiting the highly conserved bacterial 16S ribosomal RNA gene, has shed new light on the bacteria with which we share our cutaneous interface. Indeed, we are only now beginning to discover ways in which the cutaneous microbiome can influence, and perhaps shape, the immune system. The corollary, namely the extent to which host genetic factors and environmental influences regulate the microbiome, perhaps via antimicrobial peptide and cytokine expression, is of special interest in efforts to gain a better understanding of the pathogenesis of chronic inflammatory skin disorders, particularly psoriasis. This review briefly describes the technology that underpins research into the cutaneous microbiome before charting our current understanding of its physiological composition. Drawing on lessons from chronic inflammatory skin and bowel diseases, specifically highlighting psoriasis, we illustrate how the concept of dysbiosis (bacterial imbalance owing to a breakdown in tolerance to commensal bacteria) 6 may underpin a range of chronic diseases. We conclude by presenting an integrated concept that shows how resident bacteria can be used to provide new insights into disease pathophysiology, and more importantly, how the microbiome can be exploited to develop novel therapeutic targets, thereby harnessing the power of sequencing in the clinic.
High-throughput next-generation sequencing made simple
The use of 16S rRNA next-generation sequencing, taking advantage of both the highly conserved and hypervariable regions of the prokaryotic 16S ribosomal gene, has facilitated a marked expansion in our understanding of the range of bacteria that colonize human skin. 7, 8 The Human Microbiome Project 9 was a large international collaborative effort that used 16S rRNA sequencing to chart the human microbiome, sampling diverse body habitats in almost 250 individuals. This study provided the basis for a dramatic expansion in metagenomic data. 10 The basic sequencing process initially involves obtaining skin swabs, washings, scrapings or biopsies. The majority of published skin microbiome data is based on results obtained from skin swabbing, with only a handful of studies utilizing skin biopsies.
11,12
Although sampling technique may theoretically affect the bacterial species identified, Grice et al. 12 found little evidence of a significant effect when comparing skin swabs, scrapes and biopsies. Chng et al. 13 have favoured tape-based skin sampling but reported concordance between several sampling approaches. Nevertheless, the possibility remains that skin compartmentspecific microbial signatures exist. Subsequently, DNA is isolated and the 16S rRNA gene is amplified using polymerase chain reaction and bar-coded primers. Importantly, specific hypervariable regions of the 16S gene, for example V1-V3, may be most suited to skin microbiome research based on an ability to identify members of the Firmicutes phyla down to the species level. [14] [15] [16] It is important to bear in mind that binding of the primers used to target regions of the 16S gene may also affect which bacteria are identified, leading to underrepresentation or overrepresentation of specific bacterial groups. 17 The product is then confirmed and isolated using gel electrophoresis before being sequenced on a commercial platform, for example the MiSeq sequencer (Fig. 1) . The vast amount of data generated is subsequently analysed using a range of bioinformatics programs, for example MOTHUR, 18 QIIME 19, 20 or SEQUENCE MATCH at RDP II, 21 to identify which bacteria are present, in terms of phyla, genera and even species. This classification is based on the degree of sequence similarity (usually over 97%), termed the 'operational taxonomic unit' (OTU). In addition, information can be obtained about bacterial prevalence, abundance and diversity and whether specific species are associated with disease phenotypes. Importantly, causal relationships cannot be determined by next-generation sequencing at single time points. Additionally, when using 16S as the sequencing target, the abundance of bacterial species within the microbiota can be determined. However, the dynamic content of bacterial genomes, including virulence factors and resistance mechanisms, is more difficult to capture.
The cutaneous microbiome: remarkable levels of complexity
Given the sheer structural complexity of human skin, it is perhaps unsurprising that this is reflected in the composition and regulation of the cutaneous microbiome. While skin site and cutaneous microenvironment (dry, wet or sebaceous) are recognized as the key factors that determine the composition of the microbiome, 21 It appears to be likely that an individual's physiological cutaneous microbiome is surprisingly stable over time. 22, 23, 29, 31 Indeed, individuals can actually be identified based on the microbial fingerprint they leave on the environment, for example on computer keyboards. 32 In the clinical context, the most interesting aspect of microbiome research is the extent to which skin disease alters the cutaneous microbiome, or even results from dysregulation and/or disruption of the resident bacterial flora. The initial focus of skin microbiome research was centred on atopic eczema 33, 34 given the prominent role of staphylococci in disease pathogenesis, but more recent efforts have focused on psoriasis as a useful model of chronic inflammatory disease.
Psoriasis pathophysiology: the role of bacteria
The role of bacteria, in particular streptococci, as a potential trigger factor for psoriasis was reported over half a century ago 35, 36 and led to the hypothesis that the disease itself was a T-cell-mediated autoimmune disease that is mediated by group A b-haemolytic streptococcal superantigen. 37 Moreover, while streptococci are most readily associated with the guttate subtype of psoriasis, recent evidence has suggested that streptococcal throat infections are also associated with exacerbations of chronic plaque psoriasis. 38 Streptococci have been isolated from the blood of patients with chronic plaque psoriasis and from those with guttate psoriasis, albeit with varying frequency. 39 Indeed, the role of tonsillectomy as a therapeutic intervention in psoriasis has recently been reviewed. 40 Although the role of bacteria in general, and streptococci in particular, in the pathogenesis of psoriasis remains unexplained, the association invites speculation that the disease is at least associated with changes in the composition of the microbiome. Whether changes in the cutaneous microbiome are an effect of streptococcal antigens present in the tonsils or are a primary event in the development of psoriasis remains unclear. Moreover, another interesting association between the microbiome and psoriasis has been suggested by Fry et al. 6, 41 Drawing on lessons learned from research in chronic inflammatory bowel disease, the authors propose that psoriasis may reflect an abnormal innate immune response [e.g. interleukin (IL)-23, IL-17] to the skin microbiome rather than being an autoimmune disease. 6, 41 Psoriasis, particularly severe disease, may be associated with an increased risk of inflammatory bowel disease, Crohn disease and ulcerative colitis. 42, 43 This association is supported by genetic evidence suggesting shared susceptibility loci. 44, 45 More recently, associations between Crohn disease and alterations in the gastrointestinal microbiome have been reported. [46] [47] [48] Interestingly, a reduction in Faecalibacterium prausnitzii, a member of the gastrointestinal Firmicutes phyla, was associated with an increased risk of postoperative disease relapse. 49 Decreased F. prausnitzii prevalence in stool has recently been reported in patients with psoriasis. 50 This observation supports the possibility that psoriasis is also associated with important shifts in the composition of the gastrointestinal microbiome.
To what extent is psoriasis associated with a dysregulated skin microbiome?
Turning our attention to the skin itself, the site of the characteristic plaques of psoriasis, we can pose the question 'What evidence exists to demonstrate that the cutaneous microbiome is altered in psoriasis?' One of the seminal studies that aimed to characterize the cutaneous microbiome in psoriasis was performed by Gao et al. 51 Drawing on results from an antecedent study in healthy skin, 21 the authors reported that plaques of psoriasis had the most diverse taxa, with Firmicutes forming the most abundant phylum. In fact, Firmicutes were significantly overrepresented when comparing involved and uninvolved psoriatic skin with control skin. Actinobacteria were the most prevalent and diverse phylum in healthy and uninvolved psoriatic skin, but were significantly reduced in involved skin. In contrast, Grice et al. 12 reported that Proteobacteria were the most abundant phylum in healthy skin, although in a later study the reported abundance was reduced. 22 Nevertheless, Gao et al. 51 found that Proteobacteria were more readily detected in healthy skin compared with psoriasis plaques. Clones representing the genus Streptococcus were detected significantly more frequently from involved psoriatic skin when compared with uninvolved skin. This contrasted with a significant reduction in Propionibacterium in involved skin. 51 Overall, double principal coordinate analysis revealed that there was less intraindividual variation than interindividual variation within the microbiome. Notwithstanding several methodological factors [the relatively small numbers in the study, the lack of stringent matching of patients with psoriasis to controls, the diverse extent of the psoriasis involvement (body surface area 5-20%) and the varied duration of disease (1-24 years)], significant differences in the cutaneous microbiome between healthy subjects and patients with psoriasis were readily detectable. Importantly, analysis of the microbiota by sequencing the 16S microbiome describes only the relative abundance of bacterial species, genera and phyla within the microbiota.
Relative changes of abundance in the microbiome do not necessarily represent changes in the actual number of all subpopulations. Future studies combining sequencing and culture data may address this limitation.
As part of the Human Microbiome Project, 52 a smaller cohort that formed a longitudinal substudy by Alekseyenko et al. 53 sought to determine the extent to which changes in the cutaneous microbiome were associated with psoriasis and whether these were influenced by systemic treatment. The microbiome was determined using high-throughput 16S rRNA gene sequencing and ultimately included skin swabs from 54 patients with moderate-to-severe psoriasis and 37 healthy controls, on a site-, ethnicity-and sex-matched basis. Controls were of a similar age to the patients with psoriasis. The final analysis was based on 51 triplets (healthy control, involved and contralateral uninvolved skin swabs).
Although there was a trend towards decreased bacterial diversity in psoriasis, particularly in involved skin, Firmicutes, Actinobacteria and Proteobacteria were the dominant phyla in all groups. However, in terms of bacterial genera, there were significant differences in the combined relative abundance of the major taxa (Propionibacterium, Corynebacterium, Streptococcus and Staphylococcus) between involved and uninvolved psoriatic and control skin. The scalp harboured the most distinct microbial community and skin site was a significant variable, consistent with the literature. 7, 12, 22 The mean combined relative abundance of Corynebacterium, Streptococcus and Staphylococcus actually increased from control to uninvolved to involved skin and two specific OTUs, namely Acidobacteria Gp4 and Schlegelella, were strongly associated with psoriasis status. While the authors concluded that the correlation between psoriasis severity and cutaneous microbial composition was weak, psoriasis status was a major source of variability in the microbial communities and two 'cutaneotypes' were identified. Healthy control skin was dominated by Proteobacteria, whereas psoriatic skin had a higher relative abundance of Actinobacteria and Firmicutes. In terms of temporal changes associated with systemic therapy, involved psoriatic skin consistently contained a higher proportion of Corynebacterium, Propionibacterium, Staphylococcus and Streptococcus and this actually increased slightly over time. The changes in uninvolved skin were more dynamic, with the abundance of these bacterial genera being similar to control skin at baseline, before increasing, and remaining increased, during treatment.
While this confirms the association between psoriasis and altered microbial colonization, several factors need to be borne in mind. Approximately 5% of the control population had a positive family history for psoriasis. Owing to the lack of longterm follow-up, and the bimodal peak of psoriasis incidence, it is possible that some of these subjects may have developed psoriasis after the study had been performed. The contribution of genetic factors to the cutaneous microbiome and whether changes within it are present before the clinical manifestation of psoriasis remain unclear. Interestingly, genetic polymorphisms resulting in altered filaggrin expression have recently been associated with changes in the cutaneous microbiome, along with underrepresentation of gram-positive anaerobic cocci. 54 It remains unclear whether genetic polymorphisms in the genes associated with psoriasis may also result in changes in the microbiome. However, given the increased b-defensin genomic copy number reported in psoriasis, 55 the extent to which genetically determined differences in antimicrobial peptides may alter the cutaneous microbiome in psoriasis is worth exploring. Moreover, given the recently reported antimicrobial activity of psoriasis-associated late cornified envelope (LCE) proteins, the role of LCEs in host defence and their effects on the cutaneous microbiome warrant further investigation. 56 It is interesting to note that despite the typical symmetrical pattern of psoriasis, unaffected matched sites on the contralateral body surface could be identified. This raises the question of the contribution of psoriasis phenotype to the composition of the skin microbiome. Finally, given the propensity for psoriasis to affect the extensor surfaces of the upper limbs, the use of the inner aspect of the elbow as a control skin site could be viewed critically. Despite these limitations, including the small sample size in the longitudinal substudy, Alekseyenko et al. 53, 57 confirmed the association between psoriasis and altered composition of the cutaneous microbiome. Moreover, they also highlighted the difficulties in performing psoriasis microbiome studies, which included, but were not limited to, antibiotic use, systemic and topical therapy, family history of psoriasis, psoriasis phenotype, comorbidities (including inflammatory bowel disease and psoriatic arthritis), the selection of skin sites and the inclusion of both involved and uninvolved skin in a dynamic disease process. Indeed, these factors are crucial for both standardizing and informing the methodology for future microbiome studies in psoriasis. In contrast to Alekseyenko et al., 53 Fahlen et al. 11 examined the cutaneous microbiome using skin biopsies and targeted the V3-V4 regions of the 16S rRNA gene using pyrosequencing. In a comparatively small study of 10 patients with psoriasis and 10 healthy controls, psoriasis plaques were biopsied and compared with control skin obtained during dermatosurgical procedures. Bacterial diversity (Shannon Diversity Index) was increased in the control group compared with the psoriasis group; however, this did not reach statistical significance. Unifrac analysis revealed clustering of the psoriasis samples, while the control samples had a more diverse skin flora. Consistent with other studies, 53 Firmicutes, Proteobacteria and Actinobacteria were the predominant phyla in healthy and psoriatic skin. In fact,
Actinobacteria were significantly more abundant in normal skin than in psoriatic skin (16% and 5%, respectively) and the abundance of Proteobacteria was significantly higher in samples of psoriatic skin from the trunk compared with those of the control group. At the genera level, the prevalence of streptococci exceeded that of staphylococci in psoriatic skin, whereas the reverse was seen in healthy skin. Again, site-and psoriasis-associated differences were identified, for example in the abundance of Propionibacteria, 11 although to a lesser extent than in other studies. 51, 53, 57 As outlined above, targeting the V3-V4 region of the 16S rRNA gene may have contributed to an underestimation of Propionibacteria. 17 Perhaps the most interesting difference reported by Fahlen et al. 11 was the abundance of Proteobacteria in psoriatic skin and the overrepresentation of streptococci in both psoriatic and healthy skin. In order to attempt to reconcile these seemingly divergent results, it is important to consider the methodologies used. Fahlen et al.
11 compared whole skin biopsies with control skin derived from dermatosurgical procedures that was obtained during the removal of skin lesions. The extent to which this skin had a microbial composition similar to completely healthy skin is unclear. Moreover, the previous use of antibiotics in either group was not specifically commented upon. Finally, the study concentrated on involved and healthy skin, perhaps missing more dynamic changes that may have occurred in uninvolved skin. However, given that Fahlen et al. 11 did not specifically match specimens by skin site, the detection of site-specific differences becomes even more significant. Furthermore, the attempt by Fahlen et al. 11 to capture a more complete picture of the cutaneous microbiome, by specifically including the dermis and the key adnexal structures, for example the pilosebaceous unit, should be recognized. In fact, the skin microbiome has recently been reported to include bacteria in the dermis and subcutaneous fat. 58 Ultimately, this may contribute to the development of a more nuanced understanding of the cutaneous microbiome and reveal potential skin compartment-specific regulation. Any dysregulation of this may conceivably contribute to the development of disease or altered wound healing. 20 Furthermore, given the aforementioned association between group A b-haemolytic streptococci and psoriasis, 39 the increased prevalence of streptococci in psoriatic skin, consistent with the original findings of Gao et al., 51 deserves further attention.
Utilizing microbiome data: bringing sequencing into the clinic
With these, at times, seemingly divergent data at both the level of bacteria phyla and genera, Statnikov et al. 57 sought to move the field forward by determining the feasibility of identifying the 'molecular signature(s)' of psoriasis. Using highthroughput sequencing, in combination with generalized local learning multivariate analysis techniques, three genera from the Proteobacteria phylum, Cupriavidus, Methylobacterium and Schlegelella, could be used to differentiate statistically between healthy, and involved and uninvolved psoriatic skin. It should be noted that both the V1-V3 and V3-V5 regions of the 16S rRNA gene were targeted. The move from the 'cutaneotypes' described in earlier work 53 to specific microbiome psoriasis signatures is a promising concept that awaits replication. If substantiated, such an approach would not only improve the characterization of psoriasis phenotypes or endotypes, but would also hold promise as a biomarker of response to treatment, i.e. a drug response endotype. Specifically, changes in the microbiome signature may be used to predict treatment response, or even serve as a basis for treatment selection, which is much needed at a time when the therapeutic armamentarium in psoriasis has rapidly expanded.
Can microbiome research reveal insights into the pathophysiology of inflammatory disease?
Based on the largely descriptive studies of the cutaneous microbiome in psoriasis, future research should focus on translating these findings into developing an integrated model of the pathogenesis of psoriasis, potentially unveiling new therapeutic targets. To this end, Fry et al. 6, 41 have charted the key aspects of the immune system that may be influenced by the microbiome. For example, they highlighted the potential two-way interaction between antimicrobial peptides, Toll-like receptors, peptidoglycan-recognition proteins and cytokines on commensal cutaneous bacteria. 59 Indeed, it is known that antimicrobial peptides, including cathelicidins (LL-37), play a role not only in regulating the composition of the cutaneous microbiome, but also in the regulation of bacterial function (e.g. biofilm formation) and may also act as a potential autoantigen in psoriasis (Figs 2 and 3 ).
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As it is recognized that treatments for psoriasis and other immune-mediated inflammatory diseases, particularly inflammatory bowel disease, may target shared cytokine pathways, 63 it would be interesting to investigate the extent to which microbiome research can reveal insights into the pathophysiology of inflammatory disease in general. The paradoxical development of psoriasis during tumour necrosis factor inhibitor therapy for Crohn disease is well recognized. 64 Crohn disease may be exacerbated by anti-IL-17 therapy in patients with psoriasis. 65 It is at least conceivable that the site-specific effects of biological therapies may be mediated by differences in the microbiome, or more intriguingly, by affecting skin-gut microbial cross-talk. Given the potential interplay between the gastrointestinal and cutaneous microbiomes, 50, 66 and the respective immune systems of affected patients, future studies would be advised to investigate both.
Conclusion and open questions
Given the myriad factors that can influence the cutaneous microbiome, a major remaining challenge confronting this area of research is the lack of an established standardized experimental design that enables valid comparisons between the wealth of published data. Such an approach should be built on best experimental practice and must be capable of adapting to technological advances. Perhaps a set of basic, but detailed, reporting criteria, including study population, methods of sample procurement and processing and data analysis, would serve as a useful first step in helping to interpret microbiome data. As outlined above, microbiomes differ and future work should also concentrate on addressing specific research questions and determining which regions of the hypervariable 16S gene are best targeted for specific ecological niches.
Cutaneous microbiome research to date has captured the complex nature of bacterial colonization of human skin. The complexity is highlighted by the observation that disparate bacterial communities are supported and sustained in regions of skin that are often only a few centimetres apart. The regulation of the microbiome in anatomically distinct skin locations (even within skin compartments), its effect on the cutaneous immune system and its potential role in disease pathogenesis will likely form the basis of intense research activity over the next decade. Only carefully designed, large, prospective controlled longitudinal studies will help to address the perennial 'cause and effect' question that often overshadows microbiome studies. Clearly establishing the extent to which bacteria play a role in the pathogenesis of psoriasis is crucial for providing a rationale for antibacterial therapy in an age of increasing antibiotic resistance.
To date, the nature of human cutaneous microbiome research has been largely descriptive; now, the key challenge is to utilize this wealth of data in order to improve patient care. Future studies should address the extent to which the skin microbiome contributes to, or indeed is protective against, the development of disease. In addition, the potential use of microbiome research to aid treatment selection or even predict treatment response, in the age of personalized medicine, remains an exciting possibility. A comprehensive and nuanced understanding of the cutaneous microbiome in health and disease, which includes not only bacteria but also fungi (especially Malassezia) 67 and viruses, and recognizes that there is in fact no single 'skin microbiome' but rather site and skin microenvironment-dependent cutaneous bacterial populations, may deepen our understanding of cutaneous (patho)physiology and help to identify new therapeutic strategies and targets. Therefore, perhaps the major challenge facing research on the cutaneous microbiome is to establish the extent to which it can be modulated. In addition to modulation using antibiotics (topical or systemic) or antiseptics, such modulation can be either direct intraindividual (or even interindividual) skin microbiome transplantation or indirect via cross-talk with the gastrointestinal microbiome (prebiotic and probiotic application), and could provide novel strategies in the management of psoriasis.
